Health Canada has new API guidelines; New Xcelience plant aims for EU market;

> A report says Medicare has the ability to cut off payments for drugs made by compounders under large manufacturing conditions but it is unclear how often it does so. Story

> Health Canada has published new draft guidelines for GMP of active pharmaceutical ingredients and is seeking responses. Release

> Israel-based BiondVax Pharmaceuticals says its manufacturing plant has passed an EU GMP inspection. Release

> Xcelience has opened a new plant in Tampa, FL, and it intends to make clinical trial supplies for markets outside the U.S. there. Story

And Finally... Indian drug manufacturer Aurobindo has told investors that it has upgraded a cephalosporin plant that the FDA placed under an import alert earlier this year and expects it to be approved to again ship APIs to the U.S. by the end of the year. Story

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.